188Re-N-DEDC Lipiodol for Treatment of Hepatocellular Carcinoma (HCC)—A Clinical and Prospective Study to Assess In-Vivo Distribution in Patients and Clinical Feasibility of Therapy
| العنوان: | 188Re-N-DEDC Lipiodol for Treatment of Hepatocellular Carcinoma (HCC)—A Clinical and Prospective Study to Assess In-Vivo Distribution in Patients and Clinical Feasibility of Therapy |
|---|---|
| المؤلفون: | Naresh Kumar, Priyanka Gupta, Shamim Ahmed Shamim, Viju Chirayil, Suresh Subramanian, Madhava B. Mallia, Chandrasekhar Bal |
| المصدر: | World Journal of Nuclear Medicine. 22:114-123 |
| بيانات النشر: | Georg Thieme Verlag KG, 2023. |
| سنة النشر: | 2023 |
| الوصف: | Objective The incidence of inoperable hepatocellular carcinoma (HCC) with/without malignant portal vein thrombosis (PVT) is increasing in India for the last decade; thus, Bhabha Atomic Research Centre (BARC), Mumbai, India, developed diethydithiocarbamate (DEDC), a new transarterial radionuclide therapy (TART) agent. 188Re-N-DEDC lipiodol is an emerging radiotherapeutic agent for inoperable HCC treatment due to its simple and onsite labeling procedure, cost-effectiveness, and least radiation-induced side effects. This study aimed to evaluate in-vivo biodistribution and clinical feasibility of 188Re-N-DEDC lipiodol TART in HCC and optimization of labeling procedure to assess post-labeling stability and radiochemical yield of labeled lipiodol with 188Re-N-DEDC complex. Materials and Methods DEDC kits were obtained as gift from BARC, Mumbai. Therapy was given to 31 HCC patients. Post-therapy planar and single-photon emission computed tomography/computed tomography (SPECT/CT) imaging were performed to see tumor uptake and biodistribution. Clinical feasibility and toxicity were decided by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0). Statistical Analysis Descriptive statistics was done for data using SPSS v22. Values was expressed as mean ± standard deviation or median with range. Results Post-therapy planar and SPECT/CT imaging showed radiotracer localization in hepatic lesions. Few patients showed lungs uptake due to hepato-pulmonary shunt (lung shunt Conclusion Human biodistribution showed very high retention of radiotracer in hepatic lesions with no long-term toxicity with this therapy. The kit preparation procedure is ideally suited for a busy hospital radio-pharmacy. By this procedure, 188Re-N-DEDC lipiodol can be prepared in high radiochemical yield within a short time (∼45 minutes). Thus, 188Re-N-DEDC lipiodol can be considered for TART in advanced and/or intermediate HCC. |
| تدمد: | 1607-3312 1450-1147 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::3da5709406273c7eea971ffa64d69f44 https://doi.org/10.1055/s-0043-1764306 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........3da5709406273c7eea971ffa64d69f44 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16073312 14501147 |
|---|